Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353914 | 0.87 | MAOA (0.61) | MAOAMAOBSRCLMNA | |
| SCHEMBL29952545 | 0.84 | ALDH1A1 (0.60) | MAOAMAOBSRCHPGDKDM4E | |
| SCHEMBL29951626 | 0.84 | KMT2A (0.69) | MAOAMAOBKMT2AMEN1HPGD | |
| SCHEMBL2654762 | 0.83 | MAOA (0.43) | MAOAMAOBKMT2AMAPTMEN1 | |
| SCHEMBL2559020 | 0.82 | ALDH1A1 (0.57) | MAOAMAOBKMT2AMAPTMEN1 | |
| SCHEMBL2556267 | 0.82 | SMN1; SMN2 (0.61) | MAOAMAOBKMT2AMEN1SRC | |
| SCHEMBL13932642 | 0.82 | UNG (0.54) | MAOAMAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL15329632 | 0.81 | ALDH1A1 (0.58) | MAOAMAOBKMT2ASRCALDH1A1 | |
| SCHEMBL6541246 | 0.81 | ALDH1A1 (0.60) | MAOAMAOBKMT2AMEN1SRC | |
| SCHEMBL2560052 | 0.81 | MAOA (0.46) | MAOAMAOBKMT2AMEN1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585517-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004062663-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | MAOA 2189/4885MAOB 1115/4885KMT2A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.